Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

R Andrew Moore, Helen Gaskell, Peter Rose, Jonathan Allan, R Andrew Moore, Helen Gaskell, Peter Rose, Jonathan Allan

Abstract

Background: Recommendations given for intravenous iron treatment are typically not supported by a high level of evidence. This meta-analysis addressed this by summarising the available date from clinical trials of ferric carboxymaltose using clinical trial reports and published reports.

Methods: Clinical trial reports were supplemented by electronic literature searches comparing ferric carboxymaltose with active comparators or placebo. Various outcomes were sought for efficacy (attainment of normal haemoglobin (Hb), increase of Hb by a defined amount, for example), together with measures of harm, including serious adverse events and deaths.

Results: Fourteen studies were identified with 2,348 randomised patients exposed to ferric carboxymaltose, 832 to oral iron, 762 to placebo, and 384 to intravenous iron sucrose. Additional data were available from cohort studies. Intravenous ferric carboxymaltose was given up to the calculated iron deficit (up to 1,000 mg in one week) for iron deficiency anaemia secondary to chronic kidney disease, blood loss in obstetric and gynaecological conditions, gastrointestinal disease, and other conditions like heart failure. The most common comparator was oral iron, and trials lasted 1 to 24 weeks. Intravenous ferric carboxymaltose improved mean Hb, serum ferritin, and transferrin saturation levels; the mean end-of-trial increase over oral iron was, for Hb 4.8 (95% confidence interval 3.3 to 6.3) g/L, for ferritin 163 (153 to 173) μg/L, and for transferrin saturation 5.3% (3.7 to 6.8%). Ferric carboxymaltose was significantly better than comparator in achievement of target Hb increase (number needed to treat (NNT) 6.8; 5.3 to 9.7) and target Hb NNT (5.9; 4.7 to 8.1). Serious adverse events and deaths were similar in incidence in ferric carboxymaltose and comparators; rates of constipation, diarrhoea, and nausea or vomiting were lower than with oral iron.

Conclusions: This review examined the available trials of intravenous ferric carboxymaltose using details from published papers and unpublished clinical trial reports. It increases the evidence available to support recommendations given for intravenous iron treatment, but there are limited trial data comparing different intravenous iron preparations.

Figures

Figure 1
Figure 1
Time course for Hb changes.
Figure 2
Figure 2
Time course for serum ferritin changes.
Figure 3
Figure 3
Time course for TSAT changes.
Figure 4
Figure 4
L'Abbé plots for percentage of patients achieving a target Hb increase (yellow with oral iron comparator, red for intravenous iron sucrose (Venofer)). Each symbol represents one trial, with size of symbol proportional to number of patients randomised using the inset scale.
Figure 5
Figure 5
L'Abbé plots for percentage of patients achieving a target Hb (yellow with oral iron comparator). Each symbol represents one trial, with size of symbol proportional to number of patients randomised using the inset scale.
Figure 6
Figure 6
L'Abbé plots for percentage of patients achieving clinical success, however defined (yellow with oral iron comparator, red for intravenous iron sucrose (Venofer)). Each symbol represents one trial, with size of symbol proportional to number of patients randomised using the inset scale.
Figure 7
Figure 7
Time course of Hb responders.
Figure 8
Figure 8
Mean improvements with intravenous ferric carboxymaltose and oral iron, for Hb (8a), ferritin (8b), and TSAT (8c).

References

    1. de Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993-2005. WHO Global Database on Anaemia, World Health Organisation; 2008.
    1. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008;8:1. doi: 10.1186/1471-2318-8-1.
    1. National Institute for Health and Clinical Excellence. Clinical guideline 39: Anaemia management in people with chronic kidney disease (CKD) 2006. (last accessed February 3 2011)
    1. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med. 2003;13:205–218. doi: 10.1046/j.1365-3148.2003.00443.x.
    1. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50:753–765. doi: 10.1111/j.1537-2995.2009.02518.x.
    1. NHS Blood and Transplant. Annual review 2010. (last accessed February 3 2011)
    1. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13:928–1936.
    1. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE) J Am Coll Cardiol. 2003;41:1933–1939. doi: 10.1016/S0735-1097(03)00425-X.
    1. Langston RD, Presley R, Flanders WD, McClellan WM. Renal insufficiency and anemia are independent risk factors for death among people with acute myocardial infarction. Kidney Int. 2003;64:1398–1405. doi: 10.1046/j.1523-1755.2003.00200.x.
    1. Patel KV, Longo DL, Ershler WB, Yu B, Semba RD, Ferrucci L, Guralnik JM. Haemoglobin concentration and the risk of death in older adults: differences by race/ethnicity in the NHANES III follow-up. Br J Haematol. 2009;145:514–523. doi: 10.1111/j.1365-2141.2009.07659.x.
    1. Teng TH, Finn J, Hung J. Mild anaemia is associated with increased all-cause mortality in heart failure. Heart Lung Circ. 2010;19:31–37. doi: 10.1016/j.hlc.2009.08.004.
    1. Zoppini G, Targher G, Chonchol M, Negri C, Stoico V, Pichiri I, Lippi G, Muggeo M, Bonora E. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis. 2010;210:575–580. doi: 10.1016/j.atherosclerosis.2009.12.008.
    1. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–388. doi: 10.1016/S0140-6736(07)60194-9.
    1. Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009;97:185–197. doi: 10.1111/j.1423-0410.2009.01207.x.
    1. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8:629–638. doi: 10.1111/j.1524-4733.2005.00058.x.
    1. Pugh-Clarke K, Cooper L, Turner J, Fermin J. An evidence-based approach to anaemia management in predialysis chronic kidney disease. J Ren Care. 2009;35(Suppl 2):29–31.
    1. Besarab A, Hörl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009;14(Suppl 1):22–33.
    1. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev. 2008;13:393–404. doi: 10.1007/s10741-008-9086-x.
    1. Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol. 2009;25:122–128. doi: 10.1097/MOG.0b013e32831ef1cd.
    1. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507–1523. doi: 10.1111/j.1365-2036.2006.03146.x.
    1. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008;52:897–906. doi: 10.1053/j.ajkd.2008.05.033.
    1. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin. 2010;26:473–482. doi: 10.1185/03007990903512461.
    1. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–1307. doi: 10.1111/j.1572-0241.2008.01846.x.
    1. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005;20:1443–1449. doi: 10.1093/ndt/gfh820.
    1. Kovesdy CP, Kalantar-Zadeh K. Iron therapy in chronic kidney disease: current controversies. J Ren Care. 2009;35(Suppl 2):14–24.
    1. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989;299:157–158. doi: 10.1136/bmj.299.6692.157.
    1. Tagboto S, Cropper L, Turner J, Pugh-Clarke K. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care. 2009;35:18–23. doi: 10.1111/j.1755-6686.2009.00075.x.
    1. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010;303:857–864. doi: 10.1001/jama.2010.206.
    1. Folb PI. The safety of iron dextran and a comparison with iron sucrose for intravenous use: a short report to the world health organization advisory committee on the safety of medicines. (last accessed February 3 2011)
    1. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739–756. doi: 10.2165/00003495-200969060-00007.
    1. Muñoz M, Breymann C, García-Erce JA, Gómez-Ramírez S, Comin J, Bisbe E. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang. 2008;94:172–183. doi: 10.1111/j.1423-0410.2007.01014.x.
    1. Moore RA, Edwards JE, McQuay HJ. Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. 2002;2:6. doi: 10.1186/1471-2490-2-6.
    1. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644–665. doi: 10.1186/ar1704.
    1. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther. 2008;10:R53. doi: 10.1186/ar2422.
    1. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010;14:47–54. doi: 10.1111/j.1542-4758.2009.00409.x.
    1. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60:345–353.
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4.
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224–233.
    1. Morris JA, Gardner MJ. In: Statistics with confidence: confidence intervals and statistical guidelines. Gardner MJ, Altman DG, editor. London: British Medical Journal; 1995. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates; pp. 50–63.
    1. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712–720.
    1. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–2728. doi: 10.1111/j.1537-2995.2009.02327.x.
    1. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448. doi: 10.1056/NEJMoa0908355.
    1. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology. 2011. in press .
    1. Clinical Study Report 1VIT04004. Vifor Pharmaceuticals. Data on file. Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (VIT-45) Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease. 2007.
    1. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2010.
    1. Clinical Study Report VIT-IV-CL-015. Vifor Pharmaceuticals. Data on file. A multicentre, controlled Phase III Study to Compare the Efficacy and Safety of VIT-45 and Venofer in the Treatment of Iron Deficiency Anaemia Associated with Chronic Renal Failure in Patients on Haemodialysis. 2005.
    1. Clinical Study Report 1VIT04005. Vifor Pharmaceuticals. Data on file. Open Label Extrension Study Evaluating the Long Term safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT-45 in the Treatment of Anemia in Non-Dialysis Dependent (NDD) Chronic Kidney Disease (CKD) 2007.
    1. Clinical Study Report 53214. Vifor Pharmaceuticals. Data on file. A multicentre, open-label, single-arm study to investigate the safety and efficacy of intravenous VIT-45 in haemodialysis patients with anaemia. 2004.
    1. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25:2722–2730. doi: 10.1093/ndt/gfq069.
    1. Clinical Study Report VIT-IV-CL-009. Vifor Pharmaceuticals. Data on file. A Multicentre, Controlled, Phase III Study to Investigate the Safety and Efficacy of Intravenous Infusions of Vit-45 In Women Suffering from Post-Partum Anaemia. 2006.
    1. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101:67–73. doi: 10.1016/j.ijgo.2007.10.009.
    1. Clinical Study Report 1VIT06011. Vifor Pharmaceuticals. Data on file. The Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients. 2007.
    1. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(435):e1–7.
    1. Clinical Study Report 1VIT04002/1VIT04003. Vifor Pharmaceuticals. Data on file. Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (VIT-45) Versus Oral Iron in the Treatment of Iron Deficiency Anemia Secondary to Heavy Uterine Bleeding. 2006.
    1. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267–278. doi: 10.1097/01.AOG.0000275286.03283.18.
    1. Clinical Study Report VIT-IV-CL-03. Vifor Pharmaceuticals. Data on file. A multicentre, open-label, phase I/II, pharmacodynamic and safety study of VIT-45 given in multiple doses for up to 4 weeks to patients with moderate, stable iron deficiency anaemia secondary to a gastrointestinal disorder. 2004.
    1. Clinical Study Report VIT-IV-CL-008. Vifor Pharmaceuticals. Data on file. A Multi-Centre, Randomised, Controlled, Phase III Study to Investigate the Safety and Efficacy of Intravenous Infusions of VIT-45 in Patients with Iron Deficiency Anaemia Secondary to Chronic Inflammatory Bowel Disease. 2005.
    1. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182–1192. doi: 10.1111/j.1572-0241.2007.01744.x.
    1. Clinical Study Report 1VIT05006. Vifor Pharmaceuticals. Data on file. A Multicenter, Randomized, Blinded, Placebo-Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients with Iron Deficiency Anemia. 2006.
    1. Clinical Study Report CARS 1. Vifor Pharmaceuticals. Data on file. A pilot randomised double-blind Controlled phase III study to comparethe efficacy and safety of Ferinject® and Venofer® versus standard therapy in patients with chronic heart failure, renal failure and iron deficiency (CARS I) 2008.
    1. Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE. Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010;25:2368–2375. doi: 10.1093/ndt/gfq218.
    1. Zhang AS, Enns CA. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem. 2009;284:711–715.
    1. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10:997–1030. doi: 10.1089/ars.2007.1893.
    1. Bleackley MR, Wong AY, Hudson DM, Wu CH, Macgillivray RT. Blood iron homeostasis: newly discovered proteins and iron imbalance. Transfus Med Rev. 2009;23:103–123. doi: 10.1016/j.tmrv.2008.12.001.
    1. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49:706–15. doi: 10.1093/rheumatology/kep432.
    1. Lau JH, Gangji AS, Rabbat CG, Brimble KS. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant. 2010;25:4002–4009. doi: 10.1093/ndt/gfq330.
    1. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010;60:399–412.
    1. Knight TG, Ryan K, Schaefer CP, D'Sylva L, Durden ED. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy. J Manag Care Pharm. 2010;16:605–15.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera